CJ
MDGL icon

Caitlin John’s Madrigal Pharmaceuticals MDGL Stock Holding History

Caitlin John’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537 Sell
1
-1
-50% -$512 ﹤0.01% 935
2026
Q1 		$1.05K Hold
2
– – ﹤0.01% 794
2025
Q4 		$1.17K Hold
2
– – ﹤0.01% 778
2025
Q3 		$917 Buy
+2
New +$746 ﹤0.01% 775

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caitlin John's MDGL Position: Q2 2026 in Review

Caitlin John reduced its Madrigal Pharmaceuticals (MDGL) stake by 50% in Q2 2026, selling an estimated $512 and leaving 1 share worth $537. The position accounts for ﹤0.01% of the portfolio, ranked #935.

Caitlin John first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.17K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Caitlin John held 1 share of Madrigal Pharmaceuticals worth $537 as of Q2 2026.
  • Caitlin John sold 1 Madrigal Pharmaceuticals share in Q2 2026, an estimated $512.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Caitlin John's portfolio in Q2 2026, its #935 holding.
  • Caitlin John first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Caitlin John's Madrigal Pharmaceuticals position peaked at $1.17K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.